- Home
- OCFT vs CBIO Comparison
OCFT vs CBIO Comparison
Compare OCFT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- CBIO
- Stock Information
- Founded
- OCFT 2015
- CBIO 2003
- Country
- OCFT China
- CBIO United States
- Employees
- OCFT N/A
- CBIO N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- CBIO
- Sector
- OCFT Technology
- CBIO
- Exchange
- OCFT Nasdaq
- CBIO Nasdaq
- Market Cap
- OCFT 290.5M
- CBIO 308.0M
- IPO Year
- OCFT 2019
- CBIO N/A
- Fundamental
- Price
- OCFT $7.43
- CBIO $13.79
- Analyst Decision
- OCFT
- CBIO Strong Buy
- Analyst Count
- OCFT 0
- CBIO 4
- Target Price
- OCFT N/A
- CBIO $25.50
- AVG Volume (30 Days)
- OCFT 40.1K
- CBIO 92.1K
- Earning Date
- OCFT 08-21-2025
- CBIO 07-31-2025
- Dividend Yield
- OCFT N/A
- CBIO N/A
- EPS Growth
- OCFT N/A
- CBIO N/A
- EPS
- OCFT N/A
- CBIO N/A
- Revenue
- OCFT $260,815,958.00
- CBIO N/A
- Revenue This Year
- OCFT N/A
- CBIO N/A
- Revenue Next Year
- OCFT $6.37
- CBIO N/A
- P/E Ratio
- OCFT N/A
- CBIO N/A
- Revenue Growth
- OCFT N/A
- CBIO N/A
- 52 Week Low
- OCFT $0.87
- CBIO $10.83
- 52 Week High
- OCFT $7.64
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- OCFT 53.08
- CBIO N/A
- Support Level
- OCFT $7.38
- CBIO N/A
- Resistance Level
- OCFT $7.57
- CBIO N/A
- Average True Range (ATR)
- OCFT 0.10
- CBIO 0.00
- MACD
- OCFT -0.01
- CBIO 0.00
- Stochastic Oscillator
- OCFT 52.33
- CBIO 0.00
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.